Liraglutide
Saxenda
Sources
registry, as of 2018-01-19Stale
https://clinicaltrials.gov/study/NCT01272219
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 3731. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Fu Change From Baseline in Fasting Body Weight Liraglutide 3.0 mg (56-Week) -7.98 percent change Week 0, Week 56 Change From Baseline in Fasting Body Weight Liraglutide Placebo (56-Week) -2.62 percent change Week 0, Week 56 Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight. Liraglutide 3.0 mg (56-Week) 63.2
ClinicalTrials.gov NCT01272219 protocol and results modules
registry, as of 2017-12-29Stale
https://clinicaltrials.gov/study/NCT01272232
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 846. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with type 2 diabetes. Treatment will be added onto subj Change (%) From Baseline in Body Weight (Fasting) Liraglutide 3.0 mg -5.9 percent change Week 0, week 56 Change (%) From Baseline in Body Weight (Fasting) Liraglutide 1.8 mg -4.6 percent change Week 0, week 56 Change (%) From Baseline in Body Weight (Fasting) Liraglutide Placebo -2.0 percent change Week 0, week 56 Proportion of Subjects Losing at Least 5% of Baseli
ClinicalTrials.gov NCT01272232 protocol and results modules
registry, as of 2017-11-01Stale
https://clinicaltrials.gov/study/NCT00781937
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 422. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have medical problems such as hypertension (high blood pres Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 Lira 3.0 mg 50.5 Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 Placebo 21.9 Percentage of Subjects Who Lost More Than 10% of Fasting Body Weight From Week 0 Lira 3.0 mg 26.1 Percentage of Subjects Who Lost More Than 10% of Fasting
ClinicalTrials.gov NCT00781937 protocol and results modules
registry, as of 2023-06-07Stale
https://clinicaltrials.gov/study/NCT04605861
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients. Overall status COMPLETED. Phases PHASE3. Lead sponsor Shanghai Zhongshan Hospital. Enrollment 414. Conditions Obese; Overweight. This is a multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect and safety of Liraglutide Injection on body weight loss compared with placebo in obese or overweight adult patients with comorbidity of metabolic disorders.
ClinicalTrials.gov NCT04605861 protocol and results modules
registry, as of 2020-03-30Stale
https://clinicaltrials.gov/study/NCT02963922
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 396. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin. Change in Body Weight (%) In-trial observation period Liraglutide 3.0 mg -6.0 Percentage change Week 0, week 56 Change in Body Weight (%) In-trial observation period Placebo -1.5 Percentage change Week 0, week 56 Change in Body Weight (%) On-drug observation period Liraglutide 3.0 mg -6.5 Percentage change Week 0, week 56 Change in Body Weight (%) On-drug observation period Placebo -1.7 Percentage change Wee
ClinicalTrials.gov NCT02963922 protocol and results modules
registry, as of 2017-11-01Stale
https://clinicaltrials.gov/study/NCT01557166
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 359. Conditions Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea. This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea. Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) Liraglutide 3.0 mg -0.36 percentage of glycosylated haemoglobin Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) Placebo -0.17 percentage of glycosylated haemoglobin diarrhoea Liraglutide 3.0 mg 29 nausea Liraglutide 3.0 mg 47 vomiting Liraglutide 3.0 mg 13 diarrhoea Placebo 14 nausea Placebo 12 vomiting Placebo 5
ClinicalTrials.gov NCT01557166 protocol and results modules
registry, as of 2023-05-19Stale
https://clinicaltrials.gov/study/NCT04074161
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 338. Conditions Overweight; Obesity. This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years. This is to compare the effect on body weight in people taking semaglutide once a week or people taking liraglutide once every day. Participants will e Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) Semaglutide 2.4 mg -16.4 Percentage of body weight Baseline (week 0), week 68 Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) Liraglutide 3.0 mg -6.4 Percentage of body weight Baseline (week 0), week 68 Chan
ClinicalTrials.gov NCT04074161 protocol and results modules
registry, as of 2020-08-25Stale
https://clinicaltrials.gov/study/NCT04525300
Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Xiangya Hospital of Central South University. Enrollment 300. Conditions Obesity. We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned. Eligible participants were randomized 2:1 to once-daily subcutaneous injections of either lir
ClinicalTrials.gov NCT04525300 protocol and results modules
registry, as of 2020-07-27Stale
https://clinicaltrials.gov/study/NCT04487743
Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Xiangya Hospital of Central South University. Enrollment 300. Conditions Obesity. We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned. Eligible participants were randomized 2:1 to once-daily subcutaneous injections of either lir
ClinicalTrials.gov NCT04487743 protocol and results modules
registry, as of 2020-03-11Stale
https://clinicaltrials.gov/study/NCT02963935
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 282. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting (IBT-CMS: Intensive Behaviour Therapy for obe Change in Body Weight (%) In-trial observation period Liraglutide 3.0 mg -7.4 percent change Week 0, week 56 Change in Body Weight (%) In-trial observation period Placebo -4.0 percent change Week 0, week 56 Change in Body Weight (%) On-drug observation period Liraglutide 3.0 mg -9.1 percent change Week 0, week 56 Change in Body Weight (%) On-drug o
ClinicalTrials.gov NCT02963935 protocol and results modules
registry, as of 2020-04-27Stale
https://clinicaltrials.gov/study/NCT02918279
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 251. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity. Change in Body Weight (%) Change from week 0 to week 30 Liraglutide 3.0 mg -4.3 Percentage change (Week 0, week 30); (Week 0, week 56); (Week 56, week 82) Change in Body Weight (%) Change from week 0 to week 30 Placebo 0.4 Percentage change (Week 0, week 30); (Week 0, week 56); (Week 56, week 82) Change in Body Weight (%) Change from week 0 to week 56 Liraglutide 3.0 mg -3.2 Percentage change (Week 0, week 30); (Week 0, week 56); (Week 56, week 82) Change in Body Weight (%) Change from week 0 t
ClinicalTrials.gov NCT02918279 protocol and results modules
registry, as of 2023-07-18Stale
https://clinicaltrials.gov/study/NCT03374956
Individualized Obesity Pharmacotherapy. Overall status COMPLETED. Phases PHASE3. Lead sponsor Mayo Clinic. Enrollment 193. Conditions Obesity. The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss. deaths Intervention Group 0 deaths Control Group 0
ClinicalTrials.gov NCT03374956 protocol and results modules
registry, as of 2023-10-23Stale
https://clinicaltrials.gov/study/NCT05952882
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Mỹ Đức Hospital. Enrollment 188. Conditions Polycystic Ovary Syndrome; Obesity; Infertility, Female. Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and one of the leading causes of infertility. PCOS and obesity affect up to 12.5% - 48.3% Asian women, increase incidence of impaired glucose tolerance, type 2 diabetes and aggrava
ClinicalTrials.gov NCT05952882 protocol and results modules
registry, as of 2026-08-25Stale
https://clinicaltrials.gov/study/NCT05965908
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome. Overall status COMPLETED. Phases PHASE3. Lead sponsor Beni-Suef University. Enrollment 183. Conditions Polycystic Ovary. The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and liraglutide in infertile women with PCOs.
ClinicalTrials.gov NCT05965908 protocol and results modules
registry, as of 2019-07-26Stale
https://clinicaltrials.gov/study/NCT01234649
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM). Overall status COMPLETED. Phases PHASE3. Lead sponsor Woman's. Enrollment 153. Conditions Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus; Metabolic Syndrome; Impaired Glucose Tolerance; Disorder of Glucose Regulation. A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy. S Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline) Metformin XR Plus Liraglutide -7.2 percent change in weight from baseline Change from baseline (time 0) to study end (84 weeks) Change in Body Weight From Baseline to End of Study (Expressed as % Com
ClinicalTrials.gov NCT01234649 protocol and results modules
registry, as of 2020-01-30Stale
https://clinicaltrials.gov/study/NCT02043054
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA). Overall status COMPLETED. Phases PHASE3. Lead sponsor University of Leicester. Enrollment 90. Conditions Type 2 Diabetes Mellitus; Cardiovascular Disease. There are recent advances in therapies for the treatment of Type 2 Diabetes Mellitus (T2DM) which include the GLP1 analogues and the DPP IV inhibitors. Both of these therapies target the incretin system using different methods to elevate/maintain circulating levels of GLP1 to sub
ClinicalTrials.gov NCT02043054 protocol and results modules
registry, as of 2021-06-07Stale
https://clinicaltrials.gov/study/NCT03480022
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS. Overall status COMPLETED. Phases PHASE3. Lead sponsor Woman's. Enrollment 88. Conditions Pre Diabetes; Polycystic Ovary Syndrome; Obesity Android. There is a growing need to develop pharmacologic interventions to improve metabolic function in women with polycystic ovary syndrome (PCOS). Given that PCOS is a frequent condition and weight loss is essential but difficult to achieve, it is important to study if the effect on bo Change in Percent Body Weight Liraglutide Pen Injector (Saxenda) 5.7 percentage loss in body weight Change from baseline (time 0) to study end (32 weeks) Change in Percent Body Weight Placebo Liraglutide Pen Injector 1.4 percentage loss in body weight Change from baseline (time 0) to study end (32 weeks) deaths Liraglutide Pen Injector (Saxenda) 0 nausea
ClinicalTrials.gov NCT03480022 protocol and results modules
registry, as of 2019-12-17Stale
https://clinicaltrials.gov/study/NCT01753362
Liraglutide In Overweight Patients With Type 1 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor University at Buffalo. Enrollment 84. Conditions Type 1 Diabetes. The purpose of this study is to examine the effects of liraglutide (a drug used to treat type 2 diabetes) on glucose (sugar) control over the 26 week study period when used in addition to insulin. deaths Placebo 0 deaths Liraglutide 0
ClinicalTrials.gov NCT01753362 protocol and results modules
registry, as of 2026-07-09Stale
https://clinicaltrials.gov/study/NCT04775082
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 78. Conditions Obesity. The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either ge
ClinicalTrials.gov NCT04775082 protocol and results modules
registry, as of 2021-04-09Stale
https://clinicaltrials.gov/study/NCT03986008
Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Xiangya Hospital of Central South University. Enrollment 60. Conditions Obesity. The purpose of this studay is to evaluate the effects of Benaglutide on the treatment of subjects with obesity.
ClinicalTrials.gov NCT03986008 protocol and results modules
registry, as of 2023-07-06Stale
https://clinicaltrials.gov/study/NCT02527200
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 56. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. Change in Body Weight (Percentage [%]) From Baseline at Week 16 Part A: Liraglutide -1.7 Percent change in body weight Week 0, week 16 Change in Body Weight (Percentage [%]) From Baseline at Week 16 Part A: Placebo -0.7 Percent change in body weight Week 0, week 16 Change in Body Weight (Percentage [%]) From Baseline at Week 16 Part B: Liraglutide -1.1 Percent change in body weight Week 0, week 16 Change in Body Weight (Percentage [%]) From Baseline at Week 16 Part B: Placebo -2.2 Perc
ClinicalTrials.gov NCT02527200 protocol and results modules
registry, as of 2018-01-30Stale
https://clinicaltrials.gov/study/NCT02654665
Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Changi General Hospital. Enrollment 36. Conditions Non-alcoholic Fatty Liver Disease (NAFLD); Weight Loss; Non-alcoholic Steatohepatitis (NASH). Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging or by biopsy and absence of causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, or hereditary
ClinicalTrials.gov NCT02654665 protocol and results modules
registry, as of 2016-03-24Stale
https://clinicaltrials.gov/study/NCT02718950
Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans. Overall status UNKNOWN. Phases PHASE3. Lead sponsor University of Campinas, Brazil. Enrollment 20. Conditions Obesity; Type 2 Diabetes Mellitus. The purpose of this study is to access liraglutide influence brown adipose tissue recruitment and its thermogenic effect through hypothalamic activation in obese individuals.
ClinicalTrials.gov NCT02718950 protocol and results modules
registry, as of 2020-03-27Stale
https://clinicaltrials.gov/study/NCT04325581
Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients. Overall status COMPLETED. Phases PHASE3. Lead sponsor Post Graduate Institute of Medical Education and Research, Chandigarh. Enrollment 16. Conditions Weight Loss. Investigators postulate that the metabolic effects of LSG would be augmented with the use of liraglutide leading to additional excess weight loss, improved glucose homeostasis, decreased intrapancreatic and intrahepatic fat than either of them individually. However there are no s
ClinicalTrials.gov NCT04325581 protocol and results modules
registry, as of 2022-06-30Stale
https://clinicaltrials.gov/study/NCT02417103
Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid. Overall status TERMINATED. Phases PHASE3. Lead sponsor Universitätsklinikum Hamburg-Eppendorf. Enrollment 2. Conditions Obesity. The aim of this study is to investigate the effect of the treatment with the GLP-1 Analogon Liraglutide on the lipid metabolism an inflammation in adipose tissue.
ClinicalTrials.gov NCT02417103 protocol and results modules
registry, as of 2024-09-26Stale
https://clinicaltrials.gov/study/NCT04683237
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia. Overall status WITHDRAWN. Phases PHASE2,PHASE3. Lead sponsor Xiaojun Chen. Enrollment 0. Conditions Atypical Endometrial Hyperplasia; Obese; Fertility Issues. To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)
ClinicalTrials.gov NCT04683237 protocol and results modules
registry, as of 2020-04-17Stale
https://clinicaltrials.gov/study/NCT02453711
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 957. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. Participants With Weight Loss of ≥5% of Baseline Body Weight Semaglutide 0.05 mg 53.5 Participants With Weight Loss of ≥5% of Baseline Body Weight Semaglutide 0.1 mg 67.49 Participants With Weight Loss of ≥5% of Baseline Body Weight Semaglutide 0.2 mg 74.91 Participants With Weight Loss of ≥5% of Baseline Body Weight Semaglutide 0.3 mg 80.52 Participants With Weight Loss of ≥5% of Baseline Body Weight Semaglutide 0.4 mg 82.52 Participants With Weight Loss of ≥5% of Baseline Body
ClinicalTrials.gov NCT02453711 protocol and results modules
registry, as of 2020-08-17Stale
https://clinicaltrials.gov/study/NCT03235050
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 834. Conditions Diabetes Mellitus, Type 2. This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382 Percentage of Participants Achieving Weight Loss of ≥5% and ≥10% Placebo 3.0 Percentage of Participants Achieving Weight Loss of ≥5% and ≥10% MEDI0382 100 mcg 18.0 Percentage of Participants Achieving Weight Loss of ≥5% and ≥10% MEDI0382 200 mcg 65.0 Percentage of Participants Achieving Weight Loss of ≥5% and ≥10% MEDI0382 300 mcg 92.0 Percentage of Participants Achieving Weight Loss of ≥5% and ≥10% Placebo 11.0 Percentage of Participants Achieving Weight Loss
ClinicalTrials.gov NCT03235050 protocol and results modules
registry, as of 2024-07-05Stale
https://clinicaltrials.gov/study/NCT03856047
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 706. Conditions Overweight; Obesity. This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. As well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more phys Change in Body Weight (%) Cagrilintide 0.3 mg -6.1 Percentage point of body weight From baseline (week 0) to week 26 Change in Body Weight (%) Cagrilintide 0.6 mg -6.9 Percentage point of body weight From baseline (week 0) to week 26 Change in Body Weight (%) Cagrilintide 1.2 mg -8.5 Percentage point of body weight From baseline (week 0) to week 26 Change in Body Weight (%) Cagrilintide 2.4
ClinicalTrials.gov NCT03856047 protocol and results modules
registry, as of 2017-11-01Stale
https://clinicaltrials.gov/study/NCT00422058
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 564. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide. Trial has the following trial period Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20 Lira Placebo/Lira 2.4 mg/Lira 3.0 mg 5.6 percentage (%) of total haemoglobin Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20 Lira 1.2 mg/Lira 3.0 mg 5.58 percentage (%) of total haemoglobin Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20 Lira 1.8 mg/Lira 3.0 mg 5.6 percentage (%)
ClinicalTrials.gov NCT00422058 protocol and results modules
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
Use The safety and effectiveness of SAXENDA as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management have been established in pediatric patients aged 12 years and older with body weight above 60 kg and an initial BMI corresponding to 30 kg/m 2 or greater for a
DailyMed saxenda, indication text